BJMO - volume 13, issue 7, november 2019
A. Deschamps MBA
This article describes the changed playing field and roles of patient advocates as well as who is a patient advocate. The author also discusses the conditions that need to be created to allow the patient advocate to act with and/or instead of the patient. The ultimate measure is the patient outcome measured by the patient.
(BELG J MED ONCOL 2019;13(7):296–300)
Read moreBJMO - volume 12, issue 7, november 2018
N. van den Eede MD, A. de Paepe MD, D. Strens MSc, P. Specenier MD, PhD
We calculated the management costs from diagnosis to death of glioblastoma patients treated at the Antwerp University Hospital between 2007 and 2016. Overall, the average cost per patient from the health care payer’s perspective was €45,165 (95% confidence interval €37,204–€54,104). The major cost driving factor was hospitalisation.
(BELG J MED ONCOL 2018;12(7):334–338)
Read moreBJMO - volume 12, issue 1, february 2018
D. Verhoeven MD, PhD, F.P. Duhoux MD, PhD, E. de Azambuja MD, PhD, H. Wildiers MD, PhD, P. Vuylsteke MD, A. Barbeaux MD, N. van Damme PhD, E. Van Eycken MD
Limited literature is available about quality management in systemic treatment of breast cancer patients. Professionals are the key players in the identification and interpretation of quality indicators. The Belgian Society of Medical Oncology takes the lead in the field of quality management of systemic treatment for cancer, especially breast cancer. A narrow collaboration with the Belgian Cancer Registry will allow benchmarking. The results will be presented and discussed between peers of the society. This should lead to better outcomes for all Belgian centres. All Belgian Society of Medical Oncology members are called for active participation
(BELG J MED ONCOL 2018;12(1):15–21)
Read more
Top
